Unifi Analytics Platform Advancement Enable Users to Better Understand and improve Daily Mamogaphy Workflow

Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations has innovative updates.

Unifi Analytics enables users to better understand and improve daily mammography workflow by providing valuable insights regarding volume and time spent on screening, diagnostic, and biopsy studies. Additionally, facilities can now benchmark efficiency metrics against a comprehensive database of more than 2,500 Hologic gantries across the nation to identify opportunities for improvement. The platform also includes new features focused on paddle utilization and compression force. These features can help users improve staff performance in ways that lead to better image quality and patient satisfaction.

“As the global leader in breast health, ongoing product innovation is central to our commitment to provide cutting-edge, insight-driven solutions that improve outcomes for patients and reduce costs and improve efficiencies for healthcare facilities,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “These enhancements to Unifi Analytics, which were informed by research and customer feedback, will provide imaging centers with even more actionable insights so they have a clear path to improve overall performance.”

Initially launched in 2019, Unifi Analytics equips administrators with the modern-day tools they need to make informed business decisions, allowing imaging centers to maximize efficiency and reduce downtime in the mammography suite. By tracking the installed base of mammography devices at a facility, the web-based platform delivers statistical analyses of factors such as technologist efficiency and quality. It also enables imaging centers to maximize device utilization, identify potential risks and challenges, and benchmark performance against the national average of Hologic users. Additionally, Unifi Analytics employs advanced machine intelligence to predict end-of-life tube failures before they occur, allowing facilities to avoid costly unplanned downtime.

SourceHologic

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”